BioNTech SE Sponsored ADR BNTX

98.52 (0.74) (0.75%) as of 25 Sep
Market cap
$24.9B
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Revenue
3,019.37 3,192.65 3,247.00 3,529.99

+8 more TTM periods

Cost of Revenue
747.47 721.42 726.13 608.82
Gross Profit
2,271.90 2,471.23 2,520.87 2,921.17
R&D Expenses
2,542.39 2,479.68 2,381.48 2,445.46
SG&A Expenses
829.90 755.89 706.45 597.40
Operating Income
(2,353.28) (1,819.78) (1,589.50) (1,028.93)
Non-operating Income/Expense
427.47 435.23 400.63 451.58
Non-operating Interest Expenses
57.61 56.37 78.97 81.01
EBT
(1,925.82) (1,384.55) (1,188.88) (577.35)
Income Tax Provision
59.53 85.32 96.51 58.84
Income after Tax
(1,985.35) (1,469.87) (1,285.38) (636.19)
Net Income Common
(1,985.35) (1,469.87) (1,285.38) (636.19)
EPS (Basic)
(7.83) (5.88) (5.24) (2.63)
Gross Margin
75.24% 77.40% 77.64% 82.75%
EBIT Margin
(77.94%) (57.00%) (48.95%) (29.15%)
EBT margin
(63.78%) (43.37%) (36.61%) (16.36%)
Net Profit Margin
(65.75%) (46.04%) (39.59%) (18.02%)
Free Cash Flow Margin
16.58% 17.65% (10.05%) (34.89%)
EBITDA
(1,576.23) (1,289.80) (1,156.40) (597.45)
EBIT
(2,353.28) (1,819.78) (1,589.50) (1,028.93)
EPS (Diluted, from Cont. Ops)
(7.90) (5.95) (5.32) (2.62)
EPS (Basic, Consolidated)
(7.90) (5.95) (5.32) (2.64)
EPS (Basic, from Continuous Ops)
(7.90) (5.95) (5.32) (2.64)
Income from Continuous Operations
(1,985.35) (1,469.87) (1,285.38) (636.19)
Consolidated Net Income/Loss
(1,985.35) (1,469.87) (1,285.38) (636.19)
EBITDA Margin
(52.20%) (40.40%) (35.61%) (16.92%)
Operating Cash Flow Margin
25.12% 26.49% 15.89% (9.68%)

Fold the line items

In millions of $ except per-share values · columns are period end dates